0001493152-24-014284.txt : 20240411 0001493152-24-014284.hdr.sgml : 20240411 20240411090013 ACCESSION NUMBER: 0001493152-24-014284 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240411 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imunon, Inc. CENTRAL INDEX KEY: 0000749647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 521256615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15911 FILM NUMBER: 24837239 BUSINESS ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 BUSINESS PHONE: (609) 896-9100 MAIL ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 FORMER COMPANY: FORMER CONFORMED NAME: Celsion CORP DATE OF NAME CHANGE: 20071121 FORMER COMPANY: FORMER CONFORMED NAME: CELSION CORP DATE OF NAME CHANGE: 19980515 FORMER COMPANY: FORMER CONFORMED NAME: CHEUNG LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024)

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On April 10, 2024, Imunon, Inc. (the “Company”) received a written notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock had met or exceeded $1.00 per share for 10 consecutive business days.

On April 11, 2024, Imunon, Inc. (the “Company”) issued a press release announcing resolution of the Company’s outstanding deficiency notice from Nasdaq. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press Release dated April 11, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.

Dated: April 11, 2024	By:	/s/ Jeffrey W. Church
		Jeffrey W. Church
		Executive Vice President and Chief Financial Officer

EX-99.1 2 ex99-1.htm

Exhibit 99.1

IMUNON Reports Compliance with Nasdaq Listing Requirements

LAWRENCEVILLE, N.J. (April 11, 2024) – IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.”

IMUNON was notified by Nasdaq on December 26, 2023 that it was not in compliance with the Minimum Bid Price Requirement because its common stock had failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. To regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on April 9, 2024, the 10^th consecutive trading day when the closing bid price of the Company’s common stock was over $1.00.

IMUNON’s Executive Chairman, Michael H. Tardugno said, “Regaining compliance with the Nasdaq Minimum Bid Price Requirement is an important event as we continue to advance our dual platform technologies. We are heartened with continued support from the investment community and remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer. If the interim data are confirmed in the final readout, the observed PFS benefit would represent a clinically meaningful outcome supporting a registrational Phase III study. Further, we remain on track to begin our Phase 1 proof-of-concept clinical study in the second quarter of 2024 with a seasonal COVID-19 booster vaccine, following FDA clearance of our IND application.”

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas^®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine^®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is entering a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, market conditions and the risk that the Company may not be able to maintain compliance with Nasdaq listing requirements; unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results may not be indicative of later results in such trials; the uncertainties of and difficulties in analyzing interim clinical data; the timing of expected regulatory and business milestones; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

IMUNON	LHA Investor Relations
Jeffrey W. Church	Kim Sutton Golodetz
Executive Vice President, CFO	212-838-3777
and Corporate Secretary	Kgolodetz@lhai.com
609-482-2455
jchurch@imunon.com

####

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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imnn-20240411.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 imnn-20240411_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 imnn-20240411_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 11, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 11, 2024
Entity File Number	001-15911
Entity Registrant Name	Imunon, Inc.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 Lenox Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lawrenceville
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648-2311
City Area Code	(609)
Local Phone Number	896-9100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://imunon.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm imnn-20240411.xsd imnn-20240411_lab.xml imnn-20240411_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "IMNN", "nsuri": "http://imunon.com/20240411", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "imnn-20240411.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "imnn-20240411_lab.xml" ] }, "presentationLink": { "local": [ "imnn-20240411_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://imunon.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-014284-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014284-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000749647 2024-04-11 2024-04-11 iso4217:USD shares iso4217:USD shares false 0000749647 8-K 2024-04-11 Imunon, Inc. DE 001-15911 52-1256615 997 Lenox Drive Suite 100 Lawrenceville NJ 08648-2311 (609) 896-9100 false false false false Common stock, par value $0.01 per share IMNN NASDAQ false